DUPIXENT is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with Type 2 inflammation characterised by:1

raised blood eosinophils (EOS)
and/or raised fraction of exhaled nitric oxide (FeNO)
who are inadequately controlled with high-dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment

DUPIXENT is an injectable biologic that inhibits both
IL-4 and IL-13 signalling1–3


DUPIXENT is a biologic immunomodulator that targets more than one biomarker, unlike other available biologics1–3


Biological therapies aim to alter the immunopathogenesis leading to asthma rather than manage the downstream airway inflammation3

Other available biologics target either IgE or IL-5 whereas, DUPIXENT targets IL-4 and IL-31–3

What types of severe asthma patients can benefit from DUPIXENT?

The following criteria need to be met by your severe asthma patients:1

Patients 12 years and older with severe asthma

Patients with Type 2 inflammation, characterised by raised blood EOS and/or raised FeNO

Patients whose asthma is inadequately with high-dose ICS plus another medicinal product for maintenance treatment

These severe asthma patients require treatment that will address their Type 2 patient profile


Illustrative patient profiles. Not actual patients.

INTRODUCING THE DUPIXENT PRE-FILLED PEN


DUPIXENT can be administered via
a pre-filled pen or a syringe1


Mode of disease

Learn more about the triggers of severe asthma.

 


Find out more


Safety profile

Learn more about the safety profile of DUPIXENT.

 


Find out more


Efficacy results

Learn more about how DUPIXENT can improve asthma in adults and adolescents.



Find out more

    EOS, eosinophils; FeNO, fractional exhaled nitric oxide; ICS, inhaled corticosteroid; IL, interleukin.

    References

    1. Sanofi Genzyme. Dupixent Summary of Product Characteristics, September 2021.
    2. Gandhi NA, et al. Nat Rev Drug Discov. 2016;15:35–50.
    3. Krings JG, et al. J Allergy Clin Immunol Pract. 2019;7(5):1379–1392.
    4. Peters MC, et al. J Allergy Clin Immunol. 2014;133(2):388–394.
    5. Doran E, et al. Front Med. 2017;4:139.

MAT-GB-2004974(v4.0) | Date of preparation: February 2022